Date:	March_23th_2021		
Your Name:	Jinghan Shi		
Manuscript Title:	ISOC1 participates in D	NA damage repair and i	nflammation-related pathways to promote lung
cancer developmer	nt		
Manuscript numbe	r (if known):	TLCR-21-219	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present	None	
	manuscript (e.g., funding,		
	provision of study materials,		
	medical writing, article		
	processing charges, etc.)		
	No time limit for this item.		
		Time frame: past	36 months
2	Grants or contracts from	_√_ None	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	_√_None	
4	Consulting fees	_√_None	

5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None	
6	Payment for expert testimony	√_None	
7	Support for attending meetings and/or travel	_√_None	
8	Patents planned, issued or pending	√_None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	_√_None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	_√_None	
11	Stock or stock options	_√_None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None	
13	Other financial or non- financial interests	_√_None	

Dr. Jinghan Shi has nothing to disclose.

Please place an "X" next to the following statement to indicate your agreement:

Date:	March_23th_	2021
Your Name:	Fujun Yang	
Manuscript Title:	ISOC1 participates	in DNA damage repair and inflammation-related pathways to promote lung
cancer developme	nt	
Manuscript numbe	er (if known):	TLCR-21-219

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials,	_√_None	
	medical writing, article		
	processing charges, etc.)		
	No time limit for this item.		
		Time frame: past	36 months
2	Grants or contracts from	$_{}$ None	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	_√_None	
4	Consulting fees	_√_None	

5	Payment or honoraria for lectures, presentations, speakers bureaus,	None	
	manuscript writing or educational events		
6	Payment for expert testimony	None	
7	Support for attending meetings and/or travel	_√_None	
8	Patents planned, issued or pending	√_None	
9	Participation on a Data Safety Monitoring Board or	√_None	
	Advisory Board		
10	Leadership or fiduciary role	_√_None	
	in other board, society,		
	committee or advocacy group, paid or unpaid		
11	Stock or stock options	_√_None	
	-		
12	Receipt of equipment,	_√_None	
	materials, drugs, medical		
	writing, gifts or other services		
13	Other financial or non-	√ None	
	financial interests		

Dr. Fujun Yang has nothing to disclose.

Please place an "X" next to the following statement to indicate your agreement:

Date:	March_23th_2021		
Your Name:	Nanfeng Zhou		
Manuscript Title:	ISOC1 participates in DN	A damage repair and inflammation-related pathways to promote lu	ung
cancer developmer	nt		
Manuscript numbe	r (if known):	TLCR-21-219	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials,	_√_None	
	medical writing, article		
	processing charges, etc.)		
	No time limit for this item.		
		Time frame: past	36 months
2	Grants or contracts from	$_{}$ None	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	_√_None	
4	Consulting fees	_√_None	

5	Payment or honoraria for	_√_None	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
6	educational events		
6	Payment for expert	None	
	testimony		
7	Support for attending	√_None	
/	meetings and/or travel		
8	Patents planned, issued or	_√_None	
	pending		
9	Participation on a Data	_√_None	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	_√_None	
	in other board, society,		
	committee or advocacy group, paid or unpaid		
11	Stock or stock options	√ None	
11	Stock of Stock Options		
12	Receipt of equipment,	√ None	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	_√_None	
	financial interests		

Dr. Nanfeng Zhou has nothing to disclose.

Please place an "X" next to the following statement to indicate your agreement:

Date:	March_23th	021
Your Name:	Yan Jiang	
Manuscript Title:	ISOC1 participate	n DNA damage repair and inflammation-related pathways to promote lung
cancer developme	nt	
Manuscript numbe	er (if known):	TLCR-21-219

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials,	_√_None	
	medical writing, article		
	processing charges, etc.)		
	No time limit for this item.		
		Time frame: past	36 months
2	Grants or contracts from	$_{}$ None	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	_√_None	
4	Consulting fees	_√_None	

5	Payment or honoraria for lectures, presentations,	√_None	
	speakers bureaus, manuscript writing or educational events		
6	Payment for expert testimony	√_None	
7	Support for attending meetings and/or travel	_√_None	
8	Patents planned, issued or pending	√_None	
9	Participation on a Data Safety Monitoring Board or	√_None	
	Advisory Board		
10	Leadership or fiduciary role	_√_None	
	in other board, society,		
	committee or advocacy group, paid or unpaid		
11	Stock or stock options	_√_None	
42			
12	Receipt of equipment, materials, drugs, medical	None	
	writing, gifts or other		
12	services		
13	Other financial or non-	None	
	financial interests		

Dr. Yan Jiang has nothing to disclose.

Please place an "X" next to the following statement to indicate your agreement:

Date:	March_23th	2021
Your Name:	Yanfeng Zh	)
Manuscript Title:	ISOC1 participat	in DNA damage repair and inflammation-related pathways to promote lung
cancer developme	nt	
Manuscript numbe	er (if known):	TLCR-21-219

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present	None	
	manuscript (e.g., funding,		
	provision of study materials,		
	medical writing, article		
	processing charges, etc.)		
	No time limit for this item.		
		Time frame: past	36 months
2	Grants or contracts from	_√_ None	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	_√_None	
4	Consulting fees	_√_None	

5	Payment or honoraria for	_√_None	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
6	educational events		
6	Payment for expert	None	
	testimony		
7	Support for attending	√_None	
/	meetings and/or travel		
8	Patents planned, issued or	_√_None	
	pending		
9	Participation on a Data	_√_None	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	_√_None	
	in other board, society,		
	committee or advocacy group, paid or unpaid		
11	Stock or stock options	√ None	
11	Stock of Stock Options		
12	Receipt of equipment,	√ None	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	_√_None	
	financial interests		

Dr. Yanfeng Zhao has nothing to disclose.

Please place an "X" next to the following statement to indicate your agreement:

Date:	March_23th	021
Your Name:	<u>Junjie Zhu</u>	
Manuscript Title:_	ISOC1 participate	in DNA damage repair and inflammation-related pathways to promote lung
cancer developme	nt	
Manuscript numbe	er (if known):	TLCR-21-219

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials,	_√_None	
	medical writing, article		
	processing charges, etc.)		
	No time limit for this item.		
		Time frame: past	36 months
2	Grants or contracts from	$_{}$ None	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	_√_None	
4	Consulting fees	_√_None	

5	Payment or honoraria for lectures, presentations,	√_None	
	speakers bureaus, manuscript writing or educational events		
6	Payment for expert testimony	√_None	
7	Support for attending meetings and/or travel	_√_None	
8	Patents planned, issued or pending	√_None	
9	Participation on a Data Safety Monitoring Board or	√_None	
	Advisory Board		
10	Leadership or fiduciary role	_√_None	
	in other board, society,		
	committee or advocacy group, paid or unpaid		
11	Stock or stock options	_√_None	
42			
12	Receipt of equipment, materials, drugs, medical	None	
	writing, gifts or other		
12	services		
13	Other financial or non-	None	
	financial interests		

Dr. Junjie Zhu has nothing to disclose.

Please place an "X" next to the following statement to indicate your agreement:

Date:	March_23th_2021	
Your Name:	Arsela Prelaj	
Manuscript Title:	ISOC1 participates in DNA damage repair and infla	mmation-related pathways to promote lung
cancer developmen	nt	
Manuscript number	r (if known): TLCR-21-219	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials,	_√_None	
	medical writing, article		
	processing charges, etc.)		
	No time limit for this item.		
		Time frame: past	36 months
2	Grants or contracts from	$_{}$ None	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	_√_None	
4	Consulting fees	_√_None	

5	Payment or honoraria for lectures, presentations,	√_None	
	speakers bureaus, manuscript writing or educational events		
6	Payment for expert testimony	√_None	
7	Support for attending meetings and/or travel	_√_None	
8	Patents planned, issued or pending	√_None	
9	Participation on a Data Safety Monitoring Board or	√_None	
	Advisory Board		
10	Leadership or fiduciary role	_√_None	
	in other board, society,		
	committee or advocacy group, paid or unpaid		
11	Stock or stock options	_√_None	
42			
12	Receipt of equipment, materials, drugs, medical	None	
	writing, gifts or other		
12	services		
13	Other financial or non-	None	
	financial interests		

Dr. Arsela Prelaj has nothing to disclose.

Please place an "X" next to the following statement to indicate your agreement:

Date:	March_27th_2021	
Your Name:	Jyoti Malhotra	
Manuscript Title:	ISOC1 participates in D	NA damage repair and inflammation-related pathways to promote lung
cancer developmen	t	
Manuscript number	r (if known):	TLCR-21-219

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present	_√_None	
	manuscript (e.g., funding,		
	provision of study materials,		
	medical writing, article		
	processing charges, etc.)		
	No time limit for this item.		
		Time frame: past	36 months
2	Grants or contracts from	_√_ None	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	_√_None	
4	Consulting fees	_√_None	
	-		

5	Payment or honoraria for lectures, presentations,	None	
	speakers bureaus, manuscript writing or educational events		
6	Payment for expert	√_None	
	testimony		
7	Support for attending	None	
'	meetings and/or travel		
8	Patents planned, issued or	_√_None	
	pending		
-			
9	Participation on a Data	Astra Zeneca	Advisory board
9	Safety Monitoring Board or	Astra Zeneca Blueprint Medicines	Advisory board Advisory board
-	Safety Monitoring Board or Advisory Board	Blueprint Medicines	
9 10	Safety Monitoring Board or Advisory Board Leadership or fiduciary role	Blueprint Medicines	
-	Safety Monitoring Board or Advisory Board Leadership or fiduciary role in other board, society, committee or advocacy	Blueprint Medicines	
10	Safety Monitoring Board or Advisory Board Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	Blueprint Medicines	
-	Safety Monitoring Board or Advisory Board Leadership or fiduciary role in other board, society, committee or advocacy	Blueprint Medicines	
10	Safety Monitoring Board or Advisory Board Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	Blueprint Medicines	
10	Safety Monitoring Board or Advisory Board Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid Stock or stock options Receipt of equipment,	Blueprint Medicines	
10	Safety Monitoring Board or Advisory Board Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid Stock or stock options Receipt of equipment, materials, drugs, medical	Blueprint Medicines √_None √_None	
10	Safety Monitoring Board or Advisory Board Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid Stock or stock options Receipt of equipment,	Blueprint Medicines √_None √_None	
10	Safety Monitoring Board or Advisory Board Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid Stock or stock options Receipt of equipment, materials, drugs, medical writing, gifts or other	Blueprint Medicines √_None √_None	
10 11 12	Safety Monitoring Board or Advisory Board Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid Stock or stock options Receipt of equipment, materials, drugs, medical writing, gifts or other services	Blueprint MedicinesNone	

Dr. Malhotra has served on the Advisory Board of Astra Zeneca and Blueprint Medicines.

Please place an "X" next to the following statement to indicate your agreement:

Date:	March_23th_2021		
Your Name:	Nicola Normanno		
Manuscript Title:	ISOC1 participates in DNA	A damage repair and inflammation-related pathways to promote lu	ung
cancer development	nt		
Manuscript numbe	r (if known):	TLCR-21-219	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present	None	
	manuscript (e.g., funding,		
	provision of study materials,		
	medical writing, article		
	processing charges, etc.)		
	No time limit for this item.		
		Time frame: past	36 months
2	Grants or contracts from	_√_ None	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	_√_None	
4	Consulting fees	_√_None	

5	Payment or honoraria for lectures, presentations,	√_None	
	speakers bureaus, manuscript writing or educational events		
6	Payment for expert testimony	√_None	
7	Support for attending meetings and/or travel	_√_None	
8	Patents planned, issued or pending	√_None	
9	Participation on a Data Safety Monitoring Board or	√_None	
	Advisory Board		
10	Leadership or fiduciary role	_√_None	
	in other board, society,		
	committee or advocacy group, paid or unpaid		
11	Stock or stock options	_√_None	
42			
12	Receipt of equipment, materials, drugs, medical	None	
۱ ۱	writing, gifts or other		
12	services		
13	Other financial or non-	None	
	financial interests		

Dr. Nicola Normanno has nothing to disclose.

Please place an "X" next to the following statement to indicate your agreement:

Date:	March_23th_2021	·	
Your Name:	Elisa Danese		
Manuscript Title:	ISOC1 participates in D	NA damage repair and in	flammation-related pathways to promote lung
cancer development	nt		
Manuscript numbe	r (if known):	TLCR-21-219	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials,	_√_None	
	medical writing, article		
	processing charges, etc.)		
	No time limit for this item.		
		Time frame: past	36 months
2	Grants or contracts from	$_{}$ None	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	_√_None	
4	Consulting fees	_√_None	

5	Payment or honoraria for lectures, presentations,	√_None	
	speakers bureaus, manuscript writing or educational events		
6	Payment for expert testimony	√_None	
7	Support for attending meetings and/or travel	_√_None	
8	Patents planned, issued or pending	√_None	
9	Participation on a Data Safety Monitoring Board or	√_None	
	Advisory Board		
10	Leadership or fiduciary role	_√_None	
	in other board, society,		
	committee or advocacy group, paid or unpaid		
11	Stock or stock options	_√_None	
42			
12	Receipt of equipment, materials, drugs, medical	None	
۱ ۱	writing, gifts or other		
12	services		
13	Other financial or non-	None	
	financial interests		

Dr. Elisa Danese has nothing to disclose.

Please place an "X" next to the following statement to indicate your agreement:

Date:	March_23th_2021		
Your Name:	Andrés F. Cardona		
Manuscript Title:	ISOC1 participates in DN/	A damage repair and i	nflammation-related pathways to promote lung
cancer developme	nt		
Manuscript numbe	er (if known):	TLCR-21-219	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present	None	
	manuscript (e.g., funding,		
	provision of study materials,		
	medical writing, article		
	processing charges, etc.)		
	No time limit for this item.		
		Time frame: past	36 months
2	Grants or contracts from	_√_ None	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	_√_None	
4	Consulting fees	_√_None	

5	Payment or honoraria for lectures, presentations,	√_None	
	speakers bureaus, manuscript writing or educational events		
6	Payment for expert testimony	√_None	
7	Support for attending meetings and/or travel	_√_None	
8	Patents planned, issued or pending	√_None	
9	Participation on a Data Safety Monitoring Board or	√_None	
	Advisory Board		
10	Leadership or fiduciary role	_√_None	
	in other board, society,		
	committee or advocacy group, paid or unpaid		
11	Stock or stock options	_√_None	
42			
12	Receipt of equipment, materials, drugs, medical	None	
۱ ۱	writing, gifts or other		
12	services		
13	Other financial or non-	None	
	financial interests		

Dr. Andrés F. Cardona has nothing to disclose.

Please place an "X" next to the following statement to indicate your agreement:

Date:	March_23th_	021
Your Name:	Xuan Hong	
Manuscript Title:_	ISOC1 participates	n DNA damage repair and inflammation-related pathways to promote lung
cancer developme	nt	
Manuscript numbe	er (if known):	TLCR-21-219

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials,	_√_None	
	medical writing, article		
	processing charges, etc.)		
	No time limit for this item.		
		Time frame: past	36 months
2	Grants or contracts from	$_{}$ None	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	_√_None	
4	Consulting fees	_√_None	

5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None	
6	Payment for expert testimony	√_None	
7	Support for attending meetings and/or travel	_√_None	
8	Patents planned, issued or pending	√_None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	_√_None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	_√_None	
11	Stock or stock options	_√_None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None	
13	Other financial or non- financial interests	_√_None	

Dr. Xuan Hong has nothing to disclose.

Please place an "X" next to the following statement to indicate your agreement:

Date:	March_23th_20	1		
Your Name:	Gening Jiang			
Manuscript Title:	ISOC1 participates in	DNA damage repair and inflammation-related pathways to promote lung		
cancer development				
Manuscript numbe	r (if known):	TLCR-21-219		

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)	
		Time frame: Since the initial	planning of the work	
1	All support for the present manuscript (e.g., funding, provision of study materials,	_√_None		
	medical writing, article			
	processing charges, etc.)			
	No time limit for this item.			
	Time frame: past 36 months			
2	Grants or contracts from	$_{}$ None		
	any entity (if not indicated			
	in item #1 above).			
3	Royalties or licenses	_√_None		
4	Consulting fees	_√_None		

5 Payment or h	Payment or honoraria for	_√_None	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events	A Norse	
6	Payment for expert	_√_None	
	testimony		
7	Support for attending	√_None	
/	meetings and/or travel		
8	Patents planned, issued or	_√_None	
	pending		
9	Participation on a Data	_√_None	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	_√_None	
	in other board, society,		
	committee or advocacy group, paid or unpaid		
11	Stock or stock options	√ None	
11	Stock of Stock Options		
12	Receipt of equipment,	√ None	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non- financial interests	_√_None	

Dr. Gening Jiang has nothing to disclose.

Please place an "X" next to the following statement to indicate your agreement:

Date:	March_23th_	021
Your Name:	Xiao Song	
Manuscript Title:	ISOC1 participates	n DNA damage repair and inflammation-related pathways to promote lung
cancer developme	nt	
Manuscript numbe	er (if known):	TLCR-21-219

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)	
		Time frame: Since the initial	planning of the work	
1	All support for the present	_√_None		
	manuscript (e.g., funding,			
	provision of study materials,			
	medical writing, article			
	processing charges, etc.)			
	No time limit for this item.			
	Time frame: past 36 months			
2	Grants or contracts from	_√_ None		
	any entity (if not indicated			
	in item #1 above).			
3	Royalties or licenses	_√_None		
4	Consulting fees	_√_None		

	Payment or honoraria for lectures, presentations,	√_None	
	speakers bureaus, manuscript writing or educational events		
6	Payment for expert testimony	_√_None	
7	Support for attending meetings and/or travel	_√_None	
8	Patents planned, issued or pending	√_None	
9	Participation on a Data Safety Monitoring Board or	√_None	
	Advisory Board		
10	Leadership or fiduciary role	_√_None	
	in other board, society,		
	committee or advocacy group, paid or unpaid		
11	Stock or stock options	_√_None	
10			
12	Receipt of equipment,	None	
	materials, drugs, medical writing, gifts or other		
12	services		
13	Other financial or non- financial interests	None	

Dr. Xiao Song has nothing to disclose.

Please place an "X" next to the following statement to indicate your agreement: